Consun Pharmaceutical Group Management
Management criteria checks 3/4
Consun Pharmaceutical Group's CEO is Meng An, appointed in Jan 2024, has a tenure of less than a year. total yearly compensation is CN¥19.79M, comprised of 5.5% salary and 94.5% bonuses, including company stock and options. directly owns 2.73% of the company’s shares, worth HK$174.37M. The average tenure of the management team and the board of directors is 4.1 years and 4.1 years respectively.
Key information
Meng An
Chief executive officer
CN¥19.8m
Total compensation
| CEO salary percentage | 5.5% |
| CEO tenure | less than a year |
| CEO ownership | 2.7% |
| Management average tenure | 4.1yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
These 4 Measures Indicate That Consun Pharmaceutical Group (HKG:1681) Is Using Debt Safely
Nov 27
Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story
Oct 02Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors
Sep 26Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
Jun 12Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30
May 12Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30
Jun 01Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
May 04Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20
Apr 28Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20
Apr 07Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10
Aug 26Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly
Apr 21Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?
Mar 17Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative
Feb 19How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 29Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?
Jan 08
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly
Dec 18Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥836m |
| Mar 31 2024 | n/a | n/a | CN¥810m |
| Dec 31 2023 | CN¥20m | CN¥1m | CN¥785m |
| Sep 30 2023 | n/a | n/a | CN¥759m |
| Jun 30 2023 | n/a | n/a | CN¥734m |
| Mar 31 2023 | n/a | n/a | CN¥708m |
| Dec 31 2022 | CN¥17m | CN¥1m | CN¥683m |
| Sep 30 2022 | n/a | n/a | CN¥660m |
| Jun 30 2022 | n/a | n/a | CN¥636m |
| Mar 31 2022 | n/a | n/a | CN¥613m |
| Dec 31 2021 | CN¥14m | CN¥670k | CN¥590m |
Compensation vs Market: Meng's total compensation ($USD2.71M) is above average for companies of similar size in the Hong Kong market ($USD481.88K).
Compensation vs Earnings: Meng's compensation has been consistent with company performance over the past year.
CEO
Meng An (53 yo)
less than a year
Tenure
CN¥19,793,000
Compensation
Mr. Meng An serves as Executive Chairman of the Board at Consun Pharmaceutical Group Limited since July 9, 2021 and serves a sits Chief Executive Officer from January 17, 2024. Mr. An being the Chairman of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | less than a year | CN¥19.79m | 2.73% HK$ 174.4m | |
| Chief Scientist & Executive Director | 4.1yrs | CN¥742.00k | no data | |
| Assistant GM | 3.8yrs | CN¥774.00k | no data | |
| CFO & VP | 4.8yrs | no data | no data | |
| Assistant President | 4.9yrs | no data | no data | |
| Board Secretary | 10.7yrs | no data | no data | |
| Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd | 4.1yrs | no data | no data | |
| Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd | 4.1yrs | no data | no data |
4.1yrs
Average Tenure
53yo
Average Age
Experienced Management: 1681's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | 3.8yrs | CN¥19.79m | 2.73% HK$ 174.4m | |
| Chief Scientist & Executive Director | 12yrs | CN¥742.00k | no data | |
| Assistant GM | 3.8yrs | CN¥774.00k | no data | |
| Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd | 4.1yrs | no data | no data | |
| Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd | 4.1yrs | no data | no data | |
| Independent Non-Executive Director | 11yrs | CN¥200.00k | no data | |
| Independent Non Executive Director | 5.6yrs | CN¥200.00k | no data | |
| Non-Executive Director | 3.4yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
4.1yrs
Average Tenure
53yo
Average Age
Experienced Board: 1681's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 16:54 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Consun Pharmaceutical Group Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fangqi Dai | China Merchants Securities (HK) Co., Ltd |
| null null | CMB International Securities Limited |
| Trina Chen | Credit Suisse |